Compulsory Licensing
Contents |
Compulsory Licensing, Intellectual Property Rights and Pharmaceuticals
Internet Workshop
Compulsory Licensing: current hot spots
Tuesday 20 Feb, 7:30pm
To be held using Paltalk internet software: see the Paltalk website to download.
Program
The workshop will provide an opportunity to hear about and discuss:
· compulsory licensing and where it stands now (Sharon)
· report of WHO Commission on IPRs and Health (David)
· current disputes over IPRs in India (Upendra) and Thailand (Gillian).
Convenor: David Legge
The presentations will be brief and there will be adequate time for discussion. The workshop will not go on for more than one hour.
Technical
This workshop will be conducted via the internet in real time voice. The platform is PalTalk (download at [ttp://www.paltalk.com/en/start_chatting.shtml]).
You will need a headset with earphones plus boom microphone (less than $30 at any electronics computer stuff shop). You need a computer (PC) with Win 2000 or higher and 128 MB RAM and a sound card.
We ask those who are thinking of coming to let me as convenor know what their PT ID is so that they can be invited into the room.
For more information email david[at]phmoz.org
Resources
Facts about compulsory licensing
WTO documents give a good overview of compulsory licensing and the key dates and documents: Fact Sheet Sept 2006 [1] (note PDF file)
Technical Note on pharmaceutical patents and the TRIPS agreement [2]
MSF documents are quite illuminating in how this fits into practical usage: [3] (note PDF file), [4]
News articles
Thailand approves copycat drugs
January 30, 2007 06:06am
THAILAND'S army appointed government said today it had approved a cheap, copycat heart disease drug, the first time a developing country has ignored an international patent for such a treatment.
Full article available from The Australian: [5]
Thailand throws down gauntlet to drug giants
IN A precedent-setting challenge to global drug companies, Thailand has become the first developing country to issue a compulsory licence to manufacture a generic drug that is not AIDS related.
Follow link to Sydney Morning Herald article. [6]]
Thailand Invokes WTO Rule To Sell Generics For HIV And Heart Disease Drugs
Article Date: 30 Jan 2007 - 0:00 PST
Thailand has invoked a World Trade Organization (WTO) agreement on intellectual property rights to allow the manufacture, purchase and sale of generic versions of two drugs for heart disease and HIV/AIDS in the country.
Full article available online here
Journal articles
Please note, you will need access to the New England Journal of Medicine to read these articles. Most university libraries will provide access on site if you do not have online access.
Thailand and the Compulsory Licensing of Efavirenz' Robert Steinbrook NEJM Volume 356:544-546
Of the many medicines for human immunodeficiency virus (HIV) infection, efavirenz, a nonnucleoside reverse-transcriptase inhibitor that became available in the late 1990s, is one of the most important. For the initial treatment of adults, the combination of efavirenz and two nucleoside reverse-transcriptase inhibitors "has become a standard-of-care comparator in clinical trials," according to Hammer et al.1 Moreover, efavirenz is available in a fixed-dose combination tablet with the nucleoside analogues emtricitabine and tenofovir; this tablet is taken only once a day. Efavirenz can cause birth defects when taken during the first trimester of pregnancy, so its use is restricted in . . . .
Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines Janice M. Mueller NEJM Volume 356:541-543
In August and September 2006, patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations (NGOs) converged on the offices of Novartis in Mumbai, India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate. Gleevec (spelled Glivec outside the United States) is used to treat chronic myeloid leukemia, and Novartis has patented the drug in 35 countries. The protesters also decried the drug's high price: Novartis sells it in India (where only 5% of people have private health insurance) for $26,000 per year; generic-drug manufacturers offer the drug at less than one tenth that price....
